Bristol-Myers Squibb (BMY) Reports Pivotal Phase 3 CheckMate-227 Study Provides Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
